Published in Telemedicine Law Weekly, March 13th, 2010
"The study included clopidogrel, a selective inhibitor of CYP2C9 isozyme, to inhibit the metabolism of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.